ABSTRACT
Following outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2002 and 2012, respectively, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic emerging human coronavirus (hCoV). SARS-CoV-2 is currently causing the global coronavirus disease 2019 (COVID-19) pandemic. CoV infections in target cells may stimulate the formation of numerous double-membrane autophagosomes and induce autophagy. Several studies provided evidence that hCoV infections are closely related to various cellular aspects associated with autophagy. Autophagy may even promote hCoV infection and replication. However, so far it is unclear how hCoV infections induce autophagy and whether the autophagic machinery is necessary for viral propagation. Here, we summarize the most recent advances concerning the mutual interplay between the autophagic machinery and the three emerging hCoVs, SARS-CoV, MERS-CoV, and SARS-CoV-2 and the model system mouse hepatitis virus. We also discuss the applicability of approved and well-tolerated drugs targeting autophagy as a potential treatment against COVID-19.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Financial support
This work was supported by the National Natural Science Foundation of China [grant number 82002131], the Natural Science Foundation Project of CQ CSTC [grant numner cstc2020jcyj-msxmX0081], the Venture & Innovation Support Programme for Chongqing Overseas Returnees [grant number cx2019114], the COVID-19 Emergency Project [grant number CQMUNCP0207], and the Scientific Research Staring Foundation of Chongqing Medical University [grant number X9729] from Chongqing Medical University.